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Summary
Objectives: We sought to determine the efficacy and 
safety of a scoring balloon for the treatment of in-stent 
restenosis (ISR).
Background: The optimal therapy for ISR is not yet 
properly established and subject to many discussions. 
The GRIP
™
 Balloon (Acrostak, Switzerland) might be of 
interest for the treatment of certain types of ISR.
Methods: Between 2003 and 2009, 157 patients who 
were treated for ISR (182 lesions, 164 interventions) 
with the GRIP
™
 balloon were retrieved from our data-
base and followed clinically. The safety endpoint was the 
occurrence of immediate coronary complication (such as 
perforation or dissection). The efficacy endpoint was free-
dom from major adverse cardiac events (MACE: cardiac 
death, myocardial infarction, and target lesion revascu-
larisation) at 12-month clinical follow-up. 
Results: Mean age was 65 ± 11 years and 82% were 
men. A focal ISR was found in 54% (n = 93) of lesions. 
Additional stenting was performed in 22% of lesions 
after angioplasty with the GRIP
™
 balloon. There was no 
perforation as immediate coronary complication whereas 
localised dissection was identified in five patients (3%). 
Survival was 98% at 12 months. MACE occurred in 13% 
of patients (n = 21). Target lesion revascularisation 
(TLR) needed to be performed in 17 (11%). Myocardial 
infarction occurred in 2 (1%), and stent thrombosis 
occurred in 1 (1%) patient. MACE rates were higher in 
patients with diffuse ISR (20%) compared with focal ISR 
(7%) (p = 0.02).
Conclusions: Balloon angio-
plasty with the GRIP
™ 
balloon for 
ISR can be safely and successfully 
performed, and leads to good clinical 
outcome in patients presenting with 
focal ISR. 
Key words: in-stent restenosis; 
scoring balloon; percutaneous coro-
nary intervention  
Introduction
In-stent restenosis (ISR) used to be responsible for 
almost one million revascularisation procedures each 
year worldwide [1]. The successful launch of drug-elut-
ing stent (DES) in 2002 decreased the need for revas-
cularisation after stenting from 15–25% to currently 
5–10%, and modified the restenotic pattern to more 
focal ISR [2–7]. Stable and troponin-negative unstable 
angina are the standard clinical presentations of ISR 
but 9–19% of patients present with myocardial infarc-
tion or death due to stent thrombosis [8–13].
Several therapeutic options have been recom-
mended for the treatment of ISR: use of rotational 
atherectomy, cutting balloon, drug-eluting balloon 
(DEB), additional DES implantation, endobrachyther-
apy, or coronary artery bypass grafting (CABG) [14–
18]. Yet, based on two studies [PACCOCATH-I and –II 
and PEPCAD-II] [15, 19], DEB has been recommended 
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Abbreviations
BMS Bare metal stent
DEB Drug-eluting balloon
DES Drug-eluting stent
ISR In-stent restenosis
MACE Major adverse cardiac events
MLD Minimum lumen diameter
PCI Percutaneous coronary intervention
RVD Reference vessel diameter
ST Stent thrombosis
TLR Target lesion revascularisation
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subject included in this scientific work. The revascular-
isation risk was estimated using the surgical logistic 
EuroSCORE (European system for cardiac operative 
risk evaluation) [21].
Quantitative angiography 
Coronary angiograms were recorded before, during, 
and immediately after the intervention. Digital angio-
grams were analysed with the use of automated edge-
detection system (CAAS II, Pie Medical Imaging). 
Quantitative measurements included the diameter of 
the reference vessel, minimal luminal diameter, and 
percent diameter of stenosis (defined as the diameter 
of the reference vessel [RVD] minus the minimal lumi-
nal diameter [MLD], divided by the reference diameter 
and multiplied by 100). Quantitative measurements 
were performed before and after each angioplasty de-
vice used.
Follow-up
Data collected during clinical follow-up were: death, 
cardiac death (CD), non-fatal acute myocardial infarc-
tion (MI), target lesion revascularisation (TLR), and 
stent thrombosis (ST). Data were retrieved from the 
hospital’s electronic database. In addition to medical 
records, death records were carefully reviewed. Follow-
up angiography was performed at operator discretion. 
Definitions
The index procedure was defined as PCI with stent im-
plantation that led to ISR. ISR was defined as any lu-
minal narrowing >50% within the stent. ISR pattern 
was classified according to the Mehran classification 
and was considered focal if <10 mm (type I) or diffuse 
if >10 mm of length (type II, III and IV) [22]. All ISR 
procedures were ischaemia-driven. 
The safety endpoint was the occurrence of immedi-
ate coronary complication (perforation or dissection). 
Dissections were categorised using the NHLBI classifi-
cation [23]. The efficacy endpoint was a composite of 
cardiac death, myocardial infarction and target lesion 
revascularisation (major adverse cardiac event, or 
MACE) at 12-month follow-up. Death was classified as 
either cardiac or non-cardiac, according to the Aca-
demic Research Consortium (ARC) definition [24]. 
Deaths that could not be classified were considered car-
diac. The diagnosis of myocardial infarction after the 
intervention was established whenever new Q-waves 
of at least 0.4 seconds duration in at least 2 contiguous 
leads appeared on the electrocardiogram with an ele-
vated creatine kinase MB fraction level, or in the ab-
sence of pathologic Q waves, an elevation in creatine 
kinase levels to more than twice the upper limit of nor-
mal with an elevated creatine kinase MB or troponin I 
level. Target lesion revascularisation was defined as 
any repeat percutaneous or surgical intervention of the 
target lesion or within 5 mm of the stent edges. Stent 
for treatment of restenosis after BMS in the 2010 ESC-
guidelines on myocardial revascularisation [class IIa 
recommendation, level of evidence B] [20]. 
Because conventional balloons tend to slip out of 
the lesion during ISR-angioplasty, some balloons were 
specifically designed to address this issue and avoid po-
tential consequences of balloon slippage, such as geo-
graphical miss, dissection, or perforation. The GRIP
™
 
balloon (Acrostak, Switzerland, fig. 1) has 4 lines of 
knobs on its surface that aim to prevent balloon slip-
page and could even help  to crush tender hyperplastic 
tissue.
The purpose of this retrospective study was to eval-
uate the immediate results and the 12-month clinical 
outcome after angioplasty with GRIP
™
 balloons for 
ISR.
Materials and methods
Between 2003 and 2009, 157 patients who were treated 
for ISR (182 lesions, 162 interventions) with the GRIP
™
 
balloon at our institution were retrieved from the data-
base. Included were patients at least 18 years of age 
that had clinical evidence of stable or unstable angina 
and presented a restenotic lesion in a stented coronary 
artery. Clinical exclusion criteria were acute myocar-
dial infarction in the previous 48 hours, moderate to se-
vere renal failure (defined as creatinine clearance of 
30–60 ml/min and <30 ml/min respectively), a known 
or presumed hypersensitivity to heparin, antiplatelet 
drugs and hypersensitivity to contrast media that was 
uncontrollable with pre-medication. Patients that pre-
sented with a thrombus in the restenotic segment were 
equally excluded, as were those unable or unwilling to 
provide written, informed consent or to participate in 
follow-up.
Medical records including medical history, infor-
mation regarding the index procedure such as im-
planted stent type, clinical presentation, lesion charac-
teristics, information regarding the ISR procedure, and 
clinical outcome up to twelve months were reviewed. 
An informed written consent was obtained from every 
Figure 1
Computer simulated image of the GRIP
™
 scoring balloon (Acrostak, 
Switzerland) with 4 lines of knobs on its surface that protect against 
balloon slippage (by courtesy of Acrostak, Winterthur, Switzerland).
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Baseline data
Baseline clinical characteristics are summarised in 
table 1. Mean age was 65 ± 11 years and 82% were men. 
Dyslipidaemia, arterial hypertension, and a positive 
family history of coronary artery disease were fre-
quently encountered. Diabetes mellitus was found in 
38 patients (23%). No statistically significant differ-
ence in baseline characteristics was found between pa-
tients suffering from focal and patients with diffuse 
ISR.
Index procedure
The index procedure was performed for de novo lesions 
in 88% (n = 151) of the cases, ISR in 11% (n = 20), and 
spontaneous dissection in 1% (n = 1). Bare metal stents 
(BMS) were used in 33% (n = 57) and DES in 58% (n = 
99) of lesions. Information regarding implanted stent 
type was missing in 9% of cases.
ISR procedure
Median time from index procedure to ischaemia-driven 
ISR procedure was 24 [9–55] months without statisti-
cally significant difference between patients treated 
with BMS (27 [8–74]) and DES (19 [9–46], p = 0.2), as 
well as between focal (29 [9–54]) and diffuse ISR (16 
[8–55], p = 0.3). 
The most common presentation of ISR was stable 
angina (59%). Focal ISR was found in 54% (n = 93) of 
lesions. According to Mehran and colleagues [22], type 
IA was found in 1% (n = 2), type IB in 14% (n = 24), type 
thrombosis was defined according to ARC into definite, 
probable, and possible, and categorised into early (<30 
days), late, and very late (>1 year) [24].
Statistical analysis
Statistical analysis was performed using dedicated 
software (SPSS 18, SPSS Inc, Chicago, IL, USA). For 
continuous variables QQ plots were computed to check 
for a normal distribution. Normally distributed vari-
ables were analysed using parametric tests and non-
normally distributed data using non-parametric tests. 
Continuous variables are expressed as mean ± stand-
ard deviation or median with 25–75% interquartile 
range and differences were compared using Student’s-t 
test or Mann Whitney U test. Categorical variables are 
expressed as counts and percentages. Cumulative sur-
vival-free of MACE was depicted by computation of Ka-
plan-Meier curves. We further computed a binary lo-
gistic regression model with respect to MACE in order 
to show which variable would be able to predict their 
occurrence at 12-month follow-up.
Results
From 162 interventions included in the study, 10 were 
excluded from the analysis due to missing medical re-
cords. Of the remaining 152 interventions with a total 
of 172 lesions, 93 were classified as focal (Mehran class 
I) and 79 as diffuse (Mehran class II, III and IV).
Table 1
Baseline data.
 All (n = 172) Focal (n = 93) Diffuse (n = 79) p-value
Male, n (%) 141 (82) 77 (83) 64 (81) 0.84
Age, years ± SD 65 ± 11 64 ± 12 65 ± 10 0.53
Risk factors
 Hypertension, n (%) 110 (64) 58 (62) 52 (66) 0.87
 Smoking, n (%) 47 (27) 27 (29) 20 (25) 0.68
 Dyslipidaemia, n (%) 126 (73) 64 (69) 62 (78) 0.29
 Diabetes mellitus, n (%) 38 (22) 17 (18) 21 (27) 0.27
 Family history, n (%) 77 (45) 47 (51) 30 (38) 0.09
Medical history
 Previous MI, n (%) 93 (54) 56 (60) 36 (46) 0.91
 Previous PCI, n (%) 53 (31) 27 (29) 26 (33) 0.74
 Previous CABG, n (%) 27 (16) 16 (17) 11 (14) 0.54
Presentation at index procedure
 Stable angina, n (%) 64 (37) 35 (38) 29 (37) 0.87
 Unstable angina, n (%) 95 (55) 50 (54) 45 (57) 0.87
 Euroscore, n ± SD 4.4 ± 3.7 4.2 ± 3.6 4.6 ± 3.8 0.29
Presentation at ISR PCI
 Stable angina, n (%) 102 (59) 54 (58) 48 (61) 0.72
 Unstable angina, n (%) 70 (41) 39 (42) 31 (39) 0.72
CABG = coronary artery bypass graft surgery; ISR = in-stent restenosis; MI = myocardial infarction; PCI = percutaneous coronary  
intervention; SD = standard deviation.
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tory of revascularisation [PCI (100%, n = 20); CABG 
(40%, n = 8] than those with naïve (first) ISR [PCI 
(21%, n = 33; p <0.001); CABG (12%, n = 19; p = 0.001]. 
No significant difference was noticed with regard to 
risk factors, clinical presentation, procedural charac-
teristics, complications or clinical outcome except for a 
higher preprocedural % stenosis in the recurrent-ISR 
group (68 ± 14% vs 61 ± 17%; p = 0.06) and a reduced 
postprocedural %stenosis (4 ± 6% vs 13 ± 9%, p = 0.02) 
compared to the naïve-ISR group. 
Safety outcome
No perforation was seen as immediate coronary com-
plication. A dissection was seen in five patients (3%) af-
ter GRIP
™
 balloon inflation. All dissections were clas-
sified as localised (NHLBI type A and B) and success-
fully covered by stent implantation.
Clinical follow up
Clinical follow-up was available in 160 patients (93%). 
Mean follow-up was 771 ± 565 days. Follow-up angio-
graphy was available in 73 cases (42%). The 12-month 
clinical outcome is summarised in table 3. Survival was 
98%. MACE were achieved by 13% of patients (n = 21). 
IC in 37% (n = 64), and type ID in 2% (n = 3). Diffuse 
ISR was found in 46% (n = 79). According to Mehran’s 
classification, 32% (n = 56) were classified as type II, 
8% (n = 13) as type III (proliferative), and 6% (n = 10) 
as type IV (chronic total occlusion). 
Quantitative angiography data are given in table 
2. Intervention with the GRIP
™
 balloon improved the 
mean degree of stenosis from 62 ± 17% to 22 ± 12% (p = 
<0.001) and was the only treatment in 66% (n = 114). 
An additional intervention was performed in the re-
maining: in 8% (n = 13) of the cases additional balloon 
angioplasty with noncompliant balloons was per-
formed; in 22% (n = 38) additional stent implantation 
(DES 94%) was done, and in 4% (n = 7) both techniques 
were performed. These additional interventions led to 
a further reduction in mean degree of stenosis to 12 ± 
9% (p = 0.08). After Grip intervention, MLD (2.0 ± 0.4 
mm vs 1.8 ± 0.5 mm, p = 0.003) was higher and percent 
stenosis (19 ± 11% vs 24 ± 13%) lower in focal compare 
to diffuse lesions (p = 0.008). These differences did not 
persist at the end of the ISR procedure (p = 0.18 and 
p = 0.46 respectively, table 2). 
Patients who underwent revascularisation for re-
current (second) ISR presented more frequently a his-
Table 2
Data on index procedure and ISR PCI.
 All (n = 172) Focal (n = 93) Diffuse (n = 79) p-value
Index procedure
Indication
 De novo lesion, n (%) 151 (88) 80 (86) 71 (90) 0.61
 Restenosis, n (%) 20 (11) 12 (13) 8 (10) 0.61
 Dissection, n (%) 1 ( 1) 1 (1) 0 (0) 0.61
BMS, n (%) 57 (33) 29(31) 28 (35) 0.62
DES, n (%) 99 (58) 55 (59) 44 (56) 0.62
Median time from index to ISR-PCI, months (IQR) 23.8 (8.6–55.2) 29.1 (9.1–53.9) 15.9 (8.0–55.2) 0.3
ISR-PCI
 RVD before PCI, mm ± SD 2.5 ± 0.5 2.6 ± 0.5 2.5 ± 0.6 0.36
 MLD before PCI, mm ± SD 1.0 ± 0.4 0.9 ± 0.4 0.9 ± 0.4 0.12
 Stenosis before PCI, mm ± SD 62 ± 17 60 ± 16 65 ± 17 0.15
 RVD post Grip, mm ± SD 2.5 ± 0.5 2.6 ± 0.5 2.5 ± 0.5 0.18
 MLD post Grip, mm ± SD 2.0 ± 0.5 2.0 ± 0.4 1.8 ± 0.5 <0.01
 Stenosis post Grip, mm ± SD 22 ± 12 19 ± 11 24 ± 13 <0.01
 RVD post additional treatment, mm ± SD 2.8 ± 0.5 2.8 ± 0.5 2.7 ± 0.4 0.34
 MLD post additional treatment, mm ± SD 2.4 ± 0.5 2.5 ± 0.5 2.3 ± 0.5 0.18
 Percent stenosis post additional treatment mm ± SD 12 ± 9 11 ± 8 13 ± 10 0.46
 Balloon angioplasty after Grip, n (%) 13 (8) 10 (11) 3 (4) 0.06
 Maximum balloon pressure for Grip balloon, atm ± SD 17 ± 4.2 17 ± 4.2 17 ± 4.2 0.41
 Stenting after Grip, n (%) 38 (22) 18 (20) 20 (25) 0.21
Dissection after Grip, n (%) 5 (3) 3 (3) 2 (3) 0.79
BMS = bare metal stent; DES = drug-eluting stent; IQR = interquartile range; ISR = in-stent restenosis; MLD = minimum lumen diameter; 
PCI = percutaneous coronary intervention; RVD = reference vessel diameter; SD = standard deviation.
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Discussion
Plain balloon angioplasty to treat ISR has been inten-
sively investigated for over a decade and has been as-
sociated with suboptimal outcome as illustrated by re-
current restenosis rates of to 22–54% at six months 
[25, 26]. With the successful introduction of DES, the 
pattern of ISR evolved to more focal lesion. Moreover 
new interventional modalities have emerged like scor-
ing balloons that decrease the risk of balloon slippage 
and allow greater luminal gain than conventional an-
gioplasty balloons. Therefore, balloon dilatation with 
scoring balloons like the GRIP
™
 balloon has been con-
sidered as the first-line treatment of ISR at our institu-
tion. 
In the present observational study we found that: 
(1) Balloon angioplasty with GRIP
™
 balloons is safe. 
(2) When post-procedural result is good, plain balloon 
angioplasty is effective to treat focal ISR with 12-month 
Median time to secondary endpoint was 148 days [IQR 
105–225]. Cumulative survival free of MACE is de-
picted in figure 2. TLR was performed in 17 patients 
(11%): 13 (8%) were treated by re-PCI and 4 (3%) un-
derwent CABG. Myocardial infarction occurred in 2 pa-
tients (1%) and definite stent thrombosis occurred in 
1 patient (1%). Most of patients suffering from MACE 
had diffuse stenosis (n = 15 vs 6, p = 0.02). This trend 
was even more germane to patients treated solely with 
the GRIP
™
 balloon and is depicted in figure 2B.
ISR prediction
Binary logistic regression showed that diffuse resteno-
sis was associated with occurrence of MACE at tewlve 
months (OR 3.4; 95%CI: 1.2–9.9, p = 0.03). 
Table 3
Clinical outcome of patients undergoing PCI with the GRIP
™
 balloon for ISR at 12-month.
 All (n = 160) Focal (n = 83) Diffuse (n = 77) p-value
Any MACE, n (%) 21 (13) 6 (7) 15 (20) 0.02
Death, n (%)  4 (2) 2 (2)  2 (3) 0.66
Cardiac death, n (%)  4 (2) 2 (2)  2 (3) 0.94
Non-fatal MI, n (%)  2 (1) 0 (0)  2 (3) 0.14
TLR, n (%) 17(11) 4 (5) 13 (17) 0.01
Stent thrombosis, n (%)  1 (1) 0 (0)  1 (1) 0.29
ISR = in-stent restenosis; MACE = major adverse cardiac events; MI = myocardial infarction; PCI = percutaneous 
coronary intervention; TLR = target lesion revascularisation.
Figure 2
Survival free of MACE at 12 months according to lesion pattern in the whole population (A), and in patients treated solely with GRIP
™
 balloon (B).
ISR = in-stent restenosis; MACE = major adverse cardiac events.
A B
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eluting stents with regard to clinical endpoints such as 
TLR (3-year follow-up: 8% vs 19%, p
superiority
 = 0.07) [30] 
and achieved a significantly lower rate of late lumen 
loss. Similarly, Habara and colleagues demonstrated 
encouraging results in patients with ISR after siroli-
mus-eluting treated by DEB vs POBA (6-month TLR 
4% vs 42%, p = 0.003) [31]. Rittger and colleagues re-
ports similar results in DES-ISR with a significantly 
lower rate of late lumen loss, TLR and MACE at 
six months in patients treated by DEB (TLR 15.3% vs 
36.8%, p = 0.005; MACE 16.7% vs 50.0%, p = <0.001) 
[32]. Clinical long-term data with DEB for restenosis 
are however, still scarce.
TLR was 11% in our population, clearly higher 
than the initial reported TLR in patients treated with 
DEB for BMS restenosis (5%–6%) [15, 19, 33]. Yet, 
when compared to TLR in patients treated with DEB 
for in-DES restenosis, these rates are within the ex-
pected range (4%–18%) [31, 32, 34]. Table 4 depicts 
TLR rates for relevant DEB trials. As noted in the 
introduction conventional angioplasty was always per-
formed prior to DEB application in restenotic patients. 
Maybe the adjunction of a scoring balloon prior to DEB 
could yield to higher luminal gain and eventually even 
more favourable clinical outcomes.
In contrast, the anti-slip effect of GRIP
™
 balloons 
works well and is associated with effective angioplasty, 
especially in focal lesions. The efficacy endpoint in our 
sample was reached by a similar percentage of patients 
as previously reported [3, 8, 10, 35–38]. For instance, 
the figures are close to the recent publication of Tagli-
areni and colleagues in 213 patients undergoing PCI 
for ISR [39]. As expected, patients with focal lesions 
had a better clinical outcome than patients with diffuse 
ISR. This was solely due to lower TLR in the focal 
group. In line with this, Rathore et al. reported that a 
focal pattern of ISR after sirolimus-eluting stent im-
plantation was an independent predictor of lower re-
MACE of 7%. (3) When post-procedural result is insuf-
ficient, additional stent placement (sandwich tech-
nique) is justified and does not negatively influence 
clinical outcome. (4) Diffuse ISR is associated with 
worse outcome. As expected patients treated for a re-
current-ISR had more frequently a history of previous 
revascularisation at the index procedure. The differ-
ences observed for patients with recurrent-ISR com-
pared to patients with naïve ISR might translate a 
higher tolerance to ischaemia in patients with recur-
rent-ISR as suggested by higher degrees of stenosis at 
presentation. One can speculate that the better post-
procedural result in this latter group might translate 
the operator’s intention to avoid further TLR. 
A scoring balloon has elements placed outside of 
the balloon in order to reduce the occurrence of slip-
page during inflation for ISR and to increase the acute 
luminal gain. To date, three scoring balloons have been 
introduced in Europe [GRIP
™
 (Acrostak), Lacrosse 
NSE (Goodman) and AngioSculpt (Angioscore/Bio-
tronik)], but no data are available regarding their 
safety and efficacy to treat ISR in humans. The main 
concern of the scoring balloon is that the elements on 
its surface could lead to higher complication rates such 
as dissection, perforation, or entrapment of the scoring 
elements [27]. In the present study, no entrapment 
or perforation was observed with the GRIP™ balloon. 
Moreover, dissections were rarely observed (five cases) 
and the incidence was considered within the antici-
pated range of 10%–13% incidence based on previous 
publications [25, 28].
According to the current guidelines, DEB should be 
considered as first-line treatment for ISR after BMS. 
Paclitaxel-eluting balloons have been found superior to 
plain old balloon angioplasty (POBA) for the treatment 
of restenosis after BMS in the randomised PACCO-
CATH trial (5-year TLR 9% vs 39%, p <0.001) [29]. In 
the PEPCAD-II trial were non-inferior to paclitaxel-
Table 4
Rates of TLR in randomised controlled DEB-trials and registries.
 n = Restenotic device DEB compared with End point at TLR
Scheller et al. 2006, 2008  54 BMS Orbus X, uncoated balloon 24 months  3 (6.2%)
Unverdorben et al. 2009  66 BMS Taxus Liberté (DES) 12 months  4 (6.3%)
Silber et al. 2011 168 BMS –  8 months 10 (5.9%)
Toelg R et al. 2012  43 BMS – 12 months  2 (4.7%)
BMS total 331    19 (5.7%)
Rittger et al. 2012  72 DES POBA (not specified)  6 months 11 (15.3%)
Habara et al. 2011  25 DES POBA (not specified)  6 months  1 (4.3%)
Silber et al. 2011  87 BMS –  8 months  9 (9.8%)
Toelg R et al. 2012  38 DES – 12 months  7 (18.4%)
DES total  97    28 (12.6%)
BMS = bare metal stent; DEB = drug-eluting balloon; DES = drug-eluting stent; POBA = plain old balloon angioplasty; TLR = target lesion 
revascularisation.
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current restenosis rate [40]. In addition, Cosgrave et 
al. reported a recurrence rate following PCI for ISR in 
drug-eluting stent from 18% in patients with focal le-
sion and 51% in patients with diffuse lesion [41]; the 
incidence of TLR at 14 months was close to our findings 
with 10% and 23%, respectively. Interestingly, TLR 
rates were similar in patients treated with POBA or 
sandwich drug-eluting stent implantation (focal lesion: 
11% vs 9%, p = 0.6; diffuse lesion: 24% vs 23%, p = 1.0) 
[3]. Finally, Mishkel et al. reported higher rates of TLR 
(28.2%) and MACE (42.9%) at 12-month in 92 patients 
who were mostly treated by sandwich DES (84%) for 
ISR [42]. 
With the current therapeutical armamentarium 
including scoring, cutting, and drug-eluting balloons, 
as well as effective drug-eluting stents, such results 
underline that ISR treatment should be tailored to and 
based on ISR pattern (focal versus diffuse), presence or 
absence of stent fracture, and type of stent implanted 
(BMS, DES).
Limitations
The present study was designed as a retrospective 
analysis and therefore lacks randomisation and inten-
tion-to-treat data. Since no sample size calculations 
were performed, we acknowledge that our results may 
be affected by a type II error.  
Conclusion
Balloon angioplasty with the GRIP
™
 balloon for ISR 
can be safely and successfully performed, and leads to 
an especially good clinical outcome in patients present-
ing with focal ISR. 
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